Yesterday, near the close of trading, Valeant plunged on a report a criminal accounting probe was focusing on the company’s former CEO and CFO. Today, near the close of trading, VRX soared after a WSJ report that the company is in talks to sell its Salix stomach-drug business to Takeda for about $10 billion, and added that another bidder is also “circling.”
More as we get it, but one look at the VRX stock price over the past 24 hours, and it is obvious that the next drug Valeant should develop is one for daytrading nausea.
All other securities are trading alongside the stock, with bonds ripping and CDS suddenly tumbling as a $10 billion liquidity injection would make the risk of a near-term bankruptcy virtually non-existent, even if it means that one of the biggest Valeant cash cows is about to go away in what is now a reverse-rollup.
The post Valeant Soars On Report It May Sell Salix For $10 Billion appeared first on crude-oil.top.